Intrexon (XON) Posts Q1 Net Income of 26c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- Wall St futures rise as yields, oil dip
- Oil slips as Mideast exports, G7 stockpile ease supply concerns
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
- Citi cuts investment banking analyst program to two years - Bloomberg
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Nasdaq notches record high close as investors focus on earnings
- Francis Halzen wins Nobel Physics Prize for Antarctic 'ghost particle' hunt
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
Intrexon Announces First Quarter 2015 Financial Results
May 11, 2015 4:05 PM EDTGERMANTOWN, Md., May 11, 2015 /PRNewswire/ --Â Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its first quarter results for 2015.Â
Business Highlights and Recent Developments:
Entered into an exclusive collaboration and license agreement with the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, to develop and commercialize chimeric antigen receptor T-cell (CAR-T) cancer therapies. Utilizing Intrexon's cell engineering techniques and RheoSwitch® platform, the collaboration aims to develop leading-edge products that... More


